Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for LSTA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 8.244M
March 31, 2026 10.93M
December 31, 2025 14.86M
September 30, 2025 17.37M
June 30, 2025 21.03M
March 31, 2025 25.36M
December 31, 2024 29.57M
September 30, 2024 33.69M
June 30, 2024 38.25M
March 31, 2024 43.00M
December 31, 2023 48.15M
September 30, 2023 52.96M
June 30, 2023 57.97M
March 31, 2023 60.96M
December 31, 2022 66.58M
September 30, 2022 72.02M
June 30, 2022 82.39M
March 31, 2022 88.50M
December 31, 2021 92.25M
September 30, 2021 98.67M
June 30, 2021 104.93M
March 31, 2021 110.27M
December 31, 2020 32.50M
September 30, 2020 37.74M
June 30, 2020 33.81M
Date Value
March 31, 2020 17.24M
December 31, 2019 20.82M
September 30, 2019 25.25M
June 30, 2019 29.89M
March 31, 2019 34.73M
December 31, 2018 37.73M
September 30, 2018 41.08M
June 30, 2018 43.74M
March 31, 2018 45.59M
December 31, 2017 50.51M
September 30, 2017 53.33M
June 30, 2017 54.42M
March 31, 2017 -0.791M
December 31, 2016 24.28M
September 30, 2016 10.75M
June 30, 2016 6.050M
March 31, 2016 33.06M
December 31, 2015 23.71M
September 30, 2015 55.43M
June 30, 2015 66.38M
March 31, 2015 50.40M
December 31, 2014 58.51M
September 30, 2014 63.00M
June 30, 2014 78.04M
March 31, 2014 59.64M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics